We are live on ! Find out more
PA

PharVision Advisers Portfolio holdings

AUM $9.86M
1-Year Est. Return 9.93%
This Fund
S&P 500
This Quarter Est. Return
-7.09%
1 Year Est. Return
+9.93%
3 Year Est. Return
5 Year Est. Return
10 Year Est. Return
AUM
$9.86M
AUM Growth
-$188M
Cap. Flow
-$186M
Cap. Flow %
-1,882.29%
Top 10 Hldgs %
17.98%
Holding
708
New
41
Increased
5
Reduced
51
Closed
611

Top Buys

Rank Stock Value
1
ACVA icon
ACV Auctions
ACVA
+$194K
2
RPD icon
Rapid7
RPD
+$183K
3
EFC
Ellington Financial
EFC
+$181K
4
SAN icon
Banco Santander
SAN
+$159K
5
OSCR icon
Oscar Health
OSCR
+$155K

Top Sells

Rank Stock Value
1
EXLS icon
EXL Service
EXLS
+$830K
2
DK icon
Delek US
DK
+$724K
3
AVGO icon
Broadcom
AVGO
+$669K
4
ITRI icon
Itron
ITRI
+$666K
5
EAT icon
Brinker International
EAT
+$649K

Sector Composition

Rank Sector Weight
1 Consumer Discretionary 17.83%
2 Technology 15.87%
3 Healthcare 10.98%
4 Industrials 10.86%
5 Real Estate 9.56%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
KRO icon
76
KRONOS Worldwide
KRO
$774M
$68.6K 0.7%
+10,448
New +$59.3K
RMNI icon
77
Rimini Street
RMNI
$419M
$68K 0.69%
+20,720
New +$71.9K
CYH icon
78
Community Health Systems
CYH
$452M
$66.7K 0.68%
+22,699
New +$73.5K
HLLY icon
79
Holley
HLLY
$315M
$65.6K 0.67%
+21,381
New +$81K
SG icon
80
Sweetgreen
SG
$807M
$61.4K 0.62%
+11,827
New +$71.9K
SND icon
81
Smart Sand
SND
$211M
$59.7K 0.61%
+11,664
New +$52.6K
TLS icon
82
Telos
TLS
$334M
$58.1K 0.59%
13,871
-88,693
-86% -$419K
MDXG icon
83
MiMedx Group
MDXG
$643M
$55.1K 0.56%
13,955
-30,303
-68% -$153K
THRY icon
84
Thryv Holdings
THRY
$166M
$54.1K 0.55%
19,747
+8,506
+76% +$33.4K
AMBP icon
85
Ardagh Metal Packaging
AMBP
$2.8B
$53.6K 0.54%
13,225
-31,894
-71% -$141K
RNW icon
86
ReNew
RNW
$2.27B
$52.9K 0.54%
11,557
-1,043
-8% -$5.55K
REAX icon
87
Real Brokerage
REAX
$436M
$52.5K 0.53%
20,985
-77,499
-79% -$234K
SMWB icon
88
Similarweb
SMWB
$583M
$49.4K 0.5%
18,927
-16,757
-47% -$69.9K
UROY
89
Uranium Royalty Corp
UROY
$425M
$46K 0.47%
+12,612
New +$51.5K
IMPP icon
90
Imperial Petroleum
IMPP
$215M
$44.5K 0.45%
10,392
-20,484
-66% -$81.8K
CURI icon
91
CuriosityStream
CURI
$154M
$44.1K 0.45%
14,883
-91,189
-86% -$308K
III icon
92
Information Services Group
III
$191M
$43.5K 0.44%
+11,322
New +$55.7K
BDN
93
Brandywine Realty Trust
BDN
$547M
$43K 0.44%
15,878
-50,647
-76% -$152K
NWL icon
94
Newell Brands
NWL
$2.21B
$43K 0.44%
12,538
-84,947
-87% -$357K
WOOF icon
95
Petco
WOOF
$771M
$40.5K 0.41%
14,575
-32,507
-69% -$89.9K
API
96
Agora
API
$334M
$38.6K 0.39%
10,898
-64,783
-86% -$275K
RPAY icon
97
Repay Holdings
RPAY
$310M
$38.5K 0.39%
+14,814
New +$47.4K
A icon
98
Agilent Technologies
A
$37.5B
-4,524
Closed -$616K
ABBV icon
99
AbbVie
ABBV
$452B
-2,019
Closed -$461K
ABM icon
100
ABM Industries
ABM
$2.75B
-9,557
Closed -$404K

Similar funds

PharVision Advisers's Q1 2026 Portfolio in Review

As of Q1 2026, PharVision Advisers held 708 positions worth $9.86M, down 95% from $198M the previous quarter. Its ten largest holdings account for 18% of the portfolio.

PharVision Advisers withdrew a net $186M in Q1 2026, closing 611 positions and reducing 51 holdings. Its most notable exit was EXL Service, an estimated $830K position sold in full.

By sector, the portfolio is most concentrated in Consumer Discretionary at 18% of assets, up from 12% a quarter earlier, followed by Technology and Healthcare.

Against the trend, PharVision Advisers opened a new position in ACV Auctions worth $125K.

  • PharVision Advisers's largest Q1 2026 buy was ACV Auctions: 29,579 shares worth $125K.
  • PharVision Advisers added most to Embecta in Q1 2026, an estimated $48.4K increase.
  • PharVision Advisers's biggest Q1 2026 reduction was Herbalife, cutting an estimated $621K.
  • PharVision Advisers fully exited EXL Service in Q1 2026, selling an estimated $830K.
  • PharVision Advisers's ten largest holdings make up 18% of its $9.86M portfolio in Q1 2026.
  • PharVision Advisers opened 41 new positions and closed 611 in Q1 2026.
  • PharVision Advisers's portfolio value fell 95% quarter-over-quarter to $9.86M.

Based on PharVision Advisers's 13F filing for Q1 2026, filed 22 Apr 2026.